TSW
REGN icon

Thompson Siegel & Walmsley’s Regeneron Pharmaceuticals REGN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.03M Buy
12,882
+206
+2% +$140K 0.14% 163
2026
Q1 		$9.79M Buy
12,676
+769
+6% +$589K 0.17% 133
2025
Q4 		$9.19M Sell
11,907
-175
-1% -$119K 0.15% 148
2025
Q3 		$6.79M Buy
12,082
+996
+9% +$563K 0.11% 183
2025
Q2 		$5.82M Buy
11,086
+1,010
+10% +$564K 0.1% 196
2025
Q1 		$6.39M Buy
10,076
+2,424
+32% +$1.67M 0.11% 160
2024
Q4 		$5.45M Buy
7,652
+162
+2% +$136K 0.08% 195
2024
Q3 		$7.87M Sell
7,490
-1,124
-13% -$1.25M 0.12% 155
2024
Q2 		$9.05M Sell
8,614
-116
-1% -$112K 0.15% 138
2024
Q1 		$8.4M Sell
8,730
-2,431
-22% -$2.31M 0.13% 151
2023
Q4 		$9.8M Sell
11,161
-612
-5% -$504K 0.16% 131
2023
Q3 		$9.69M Buy
11,773
+337
+3% +$265K 0.16% 130
2023
Q2 		$8.22M Buy
11,436
+21
+0.2% +$16.2K 0.13% 158
2023
Q1 		$9.38M Buy
11,415
+423
+4% +$319K 0.15% 139
2022
Q4 		$7.93M Sell
10,992
-411
-4% -$303K 0.13% 157
2022
Q3 		$7.86M Sell
11,403
-96
-0.8% -$60.4K 0.14% 158
2022
Q2 		$6.8M Buy
11,499
+35
+0.3% +$22.8K 0.11% 167
2022
Q1 		$8.01M Buy
11,464
+71
+0.6% +$44.9K 0.11% 174
2021
Q4 		$7.2M Buy
11,393
+313
+3% +$192K 0.1% 179
2021
Q3 		$6.71M Buy
11,080
+235
+2% +$146K 0.1% 179
2021
Q2 		$6.06M Buy
+10,845
New +$5.49M 0.08% 184
2018
Q2 		– Sell
-41
Closed -$14K – 820
2018
Q1 		$14K Hold
41
– – ﹤0.01% 658
2017
Q4 		$15K Hold
41
– – ﹤0.01% 677
2017
Q3 		$18K Hold
41
– – ﹤0.01% 658
2017
Q2 		$20K Hold
41
– – ﹤0.01% 651
2017
Q1 		$16K Sell
41
-6
-13% -$2.22K ﹤0.01% 662
2016
Q4 		$17K Hold
47
– – ﹤0.01% 607
2016
Q3 		$19K Hold
47
– – ﹤0.01% 588
2016
Q2 		$16K Buy
+47
New +$18.1K ﹤0.01% 588

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Thompson Siegel & Walmsley's REGN Position: Q2 2026 in Review

Thompson Siegel & Walmsley increased its Regeneron Pharmaceuticals (REGN) stake by 1.6% in Q2 2026, buying an estimated $140K and bringing the position to 12,882 shares worth $8.03M. The position accounts for 0.14% of the portfolio, ranked #163.

Thompson Siegel & Walmsley first reported a position in REGN in Q2 2016 and has held it in 29 quarters since. The position peaked at $9.8M in Q4 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Thompson Siegel & Walmsley held 12,882 shares of Regeneron Pharmaceuticals worth $8.03M as of Q2 2026.
  • Thompson Siegel & Walmsley bought 206 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $140K.
  • Regeneron Pharmaceuticals made up 0.14% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #163 holding.
  • Thompson Siegel & Walmsley first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 29 quarters since.
  • Thompson Siegel & Walmsley's Regeneron Pharmaceuticals position peaked at $9.8M in Q4 2023.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.